Ohashi T - Search Results

1

The hearing status in 12 female and 15 male Japanese Fabry patients.

Sakurai Y, Kojima H, Shiwa M, Ohashi T, Eto Y, Moriyama H. Sakurai Y, et al. Among authors: ohashi t. Auris Nasus Larynx. 2009 Dec;36(6):627-32. doi: 10.1016/j.anl.2009.01.001. Epub 2009 Mar 3. Auris Nasus Larynx. 2009. PMID: 19261412

2

Inner ear pathology of alpha-galactosidase A deficient mice, a model of Fabry disease.

Sakurai Y, Suzuki R, Yoshida R, Kojima H, Watanabe M, Manome Y, Ohashi T, Eto Y, Moriyama H. Sakurai Y, et al. Among authors: ohashi t. Auris Nasus Larynx. 2010 Jun;37(3):274-80. doi: 10.1016/j.anl.2009.08.005. Epub 2009 Nov 8. Auris Nasus Larynx. 2010. PMID: 19900774

3

Significance of screening for Fabry disease among male dialysis patients.

Ichinose M, Nakayama M, Ohashi T, Utsunomiya Y, Kobayashi M, Eto Y. Ichinose M, et al. Among authors: ohashi t. Clin Exp Nephrol. 2005 Sep;9(3):228-32. doi: 10.1007/s10157-005-0369-4. Clin Exp Nephrol. 2005. PMID: 16189631

4

Reduced alpha-Gal A enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease.

Ohashi T, Iizuka S, Ida H, Eto Y. Ohashi T, et al. Mol Genet Metab. 2008 Jul;94(3):313-8. doi: 10.1016/j.ymgme.2008.03.008. Epub 2008 May 5. Mol Genet Metab. 2008. PMID: 18456533

5

Long-term effect of enzyme replacement therapy with fabry disease.

Komori M, Sakurai Y, Kojima H, Ohashi T, Moriyama H. Komori M, et al. Among authors: ohashi t. Int J Otolaryngol. 2013;2013:282487. doi: 10.1155/2013/282487. Epub 2013 Oct 8. Int J Otolaryngol. 2013. PMID: 24223040 Free PMC article.

6

Characteristics of Cerebral Microbleeds in Patients with Fabry Disease.

Kono Y, Wakabayashi T, Kobayashi M, Ohashi T, Eto Y, Ida H, Iguchi Y. Kono Y, et al. Among authors: ohashi t. J Stroke Cerebrovasc Dis. 2016 Jun;25(6):1320-5. doi: 10.1016/j.jstrokecerebrovasdis.2016.02.019. Epub 2016 Mar 14. J Stroke Cerebrovasc Dis. 2016. PMID: 26987491

7

Frequency of de novo mutations in Japanese patients with Fabry disease.

Kobayashi M, Ohashi T, Iizuka S, Kaneshiro E, Higuchi T, Eto Y, Ida H. Kobayashi M, et al. Among authors: ohashi t. Mol Genet Metab Rep. 2014 Aug 2;1:283-287. doi: 10.1016/j.ymgmr.2014.07.001. eCollection 2014. Mol Genet Metab Rep. 2014. PMID: 27896102 Free PMC article.

8

The beneficial effects of long-term enzyme replacement therapy on cardiac involvement in Japanese Fabry patients.

Hongo K, Ito K, Date T, Anan I, Inoue Y, Morimoto S, Ogawa K, Kawai M, Kobayashi H, Kobayashi M, Ida H, Ohashi T, Taniguchi I, Yoshimura M, Eto Y. Hongo K, et al. Among authors: ohashi t. Mol Genet Metab. 2018 Jun;124(2):143-151. doi: 10.1016/j.ymgme.2018.04.008. Epub 2018 Apr 26. Mol Genet Metab. 2018. PMID: 29747997 Clinical Trial.

9

Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy.

Ohashi T, Sakuma M, Kitagawa T, Suzuki K, Ishige N, Eto Y. Ohashi T, et al. Mol Genet Metab. 2007 Nov;92(3):271-3. doi: 10.1016/j.ymgme.2007.06.013. Epub 2007 Aug 8. Mol Genet Metab. 2007. PMID: 17689998

10

Non-invasive high-risk screening for Fabry disease hemizygotes and heterozygotes.

Kitagawa T, Suzuki K, Ishige N, Ohashi T, Kobayashi M, Eto Y, Tanaka A, Odaka H, Owada M. Kitagawa T, et al. Among authors: ohashi t. Pediatr Nephrol. 2008 Sep;23(9):1461-71. doi: 10.1007/s00467-008-0846-6. Epub 2008 Jun 6. Pediatr Nephrol. 2008. PMID: 18535844

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,461 results

Search Page